EOM

American Oncology Network Announces Participation in the Enhancing Oncology Model

Retrieved on: 
Wednesday, July 26, 2023
Heart, Partnership, Food, Housing, AON, OCM, Oncology Care Model, Health equity, Cancer, EOM, CMMI, Center for Medicare and Medicaid Innovation, Medicare, MD, Patient, Practitioner, Oncology, Transport, Caregiver, Hospital, Nursing

FORT MYERS, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON), one of the nation’s fastest-growing networks of community oncology practices, announced its participation in the Enhancing Oncology Model (EOM), a new value-based cancer care framework launched by the Center for Medicare and Medicaid Innovation (CMMI), to improve health outcomes and reduce total costs of care.

Key Points: 
  • FORT MYERS, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON), one of the nation’s fastest-growing networks of community oncology practices, announced its participation in the Enhancing Oncology Model (EOM), a new value-based cancer care framework launched by the Center for Medicare and Medicaid Innovation (CMMI), to improve health outcomes and reduce total costs of care.
  • To address the rising costs of cancer and improve care quality, CMMI launched the EOM on July 1st, 2023, a five-year voluntary program for oncology practices.
  • Built on the successes of and lessons learned from its predecessor, the Oncology Care Model (OCM), EOM is indicative of an industry paradigm shift towards value-based cancer care.
  • “Together with AON, we can accelerate EOM to achieve a better patient experience, better outcomes and lower costs of cancer care.”

ZeroSum Market First Report July 2023: New and Used Car Inventory is Down from June, but the Market is in a Much Stronger Place than One Year Ago

Retrieved on: 
Wednesday, July 26, 2023
MSRP, EV, Automotive News, COVID-19, Yahoo! News, EOM, Forecasting, EVS, MOM, Yahoo!, UBS, News, Automotive industry, Gasoline, Fireworks, Self storage

ZeroSum is forecasting July used car inventory to be at 1,922,704 by EOM.

Key Points: 
  • ZeroSum is forecasting July used car inventory to be at 1,922,704 by EOM.
  • This number slightly dipped from June's EOM number, but July's inventory is still well above the January 2023 low, which was 1,510,076.
  • In addition, less inventory on new and used vehicles makes it harder to rely on volume to drive sales.
  • New car inventory has seen some ups and downs in 2023, but overall inventory has been increasing for much of the year.

Lightbeam Health Expands Agreement with Cardinal Health to Advance Enhancing Oncology Model Initiatives

Retrieved on: 
Tuesday, July 11, 2023
Technology, Medical Supplies, Health Technology, Public Policy, Government, Healthcare Reform, Software, General Health, Pharmaceutical, Health, Oncology, Shadow King, Partnership, Doctor of Pharmacy, LCS, OCM, Oncology Care Model, Business, Cardinal, EOM, Experiment (probability theory), Light beam, Research, Social, Cardinal Health, Patient, Axxess Technology Solutions, Artificial intelligence, SVP, Schwind eye tech solutions, Nursing

The Enhancing Oncology Model (EOM) replaced the Oncology Care Model (OCM) in July 2023.

Key Points: 
  • The Enhancing Oncology Model (EOM) replaced the Oncology Care Model (OCM) in July 2023.
  • Through this expanded agreement, Cardinal Health will bolster its EOM offering with Lightbeam’s population health analytics application, Lightbeam Clinical Services (LCS) and Deviceless Remote Patient Monitoring®.
  • “Lightbeam is honored to be Cardinal Health’s trusted partner for population health enablement solutions and capabilities,” says Patrick Burton, SVP of Business Development at Lightbeam Health Solutions.
  • “With its expanded implementation of Lightbeam solutions, Navista™ TS is the all-in-one technology solution for patient-centered oncology care.

ZeroSum Market First Report June 2023: Despite a Small Bump in New Car Inventory, Prices Remain Historically High

Retrieved on: 
Tuesday, June 27, 2023
News, EVS, Human, Growth, MSRP, EOM, EV, Tesla, Automotive News, Retail, Gasoline, Nissan, Porsche, Cadillac

Used car inventory is now at the highest level in two years, with June EOM numbers estimated at 1,835,193.

Key Points: 
  • Used car inventory is now at the highest level in two years, with June EOM numbers estimated at 1,835,193.
  • Used car prices have increased again for the third straight month to an average price of $31,262, an increase of 0.15%.
  • Pure electric vehicle inventory for June is predicted at 97,820, an increase of more than 10,000 vehicles from May EOM.
  • Despite the previous several months of dropping inventory, new car prices have been steadily rising, and June was no exception.

Research Presented at ASCO 2023 Shows Implementing Value-Based Care Strategies Such as Dose Rounding Reduces Drug Waste and Total Cost of Care

Retrieved on: 
Monday, June 5, 2023
Science, Practice Management, Research, Pharmaceutical, Oncology, Health, Artificial Intelligence, Technology, Gastrointestinal cancer, NTA, Bevacizumab, BCPS, Elijah Cummings Lower Drug Costs Now Act, Doctor of Pharmacy, Network, MBBS, OCM, Oncology Care Model, Survival, Cancer, EOM, CMMI, Brain, Lung, MS, Colon, ASCO, Center for Medicare and Medicaid Innovation, American Society of Clinical Oncology, Patient, Physician, The Network, Risk, National Television Awards, Improving Medicare Post-Acute Care Transformation Act of 2014, Diagnosis, Society, Medical imaging, Pharmaceutical industry, Nursing, Medicare, MD

Waste from partially used single dose vials of expensive drugs is a leading contributor to avoidable total cost of care (TCOC) expenditures.

Key Points: 
  • Waste from partially used single dose vials of expensive drugs is a leading contributor to avoidable total cost of care (TCOC) expenditures.
  • They found:
    Drug waste led to $156 of additional TCOC per member episode per month prior to implementation of dose rounding.
  • Dose rounding resulted in a TCOC reduction of approximately $100 per member episode per month for episodes with B+B administrations in the OCM.
  • ), and in administrations where drug waste was greater than 10% of the total dose.

ZeroSum Market First Report May 2023: New and used car inventory is down for the first time in months, but prices are still rising

Retrieved on: 
Thursday, May 25, 2023
MSRP, EV, Automotive News, Global recession, Gasoline, EOM, Sale, EVS, CNBC, Federal Reserve responses to the subprime crisis, Federal Reserve, AN, Great Recession, Environment, News, Retail, Lease

Used car inventory took the first dip that we've seen since December 2022, with the predicted May EOM number landing at 1,762,346.

Key Points: 
  • Used car inventory took the first dip that we've seen since December 2022, with the predicted May EOM number landing at 1,762,346.
  • Used car prices are rising, continuing the trend ZeroSum first reported in our April 2023 Report.
  • Used car prices are up 1.34% from the start of April 2023, with the average used car price now at $31,215.
  • Car prices have been increasing, but as ZeroSum reported above, used car inventory has decreased for the first time in months.

ZeroSum Market First Report April 2023: New Vehicle Inventory is Predicted to Dip Slightly as Used Car Prices Increase for the First Time in Months

Retrieved on: 
Thursday, April 27, 2023
EVS, Tesla Model S, Growth, Yahoo! Finance, MSRP, Tesla, EV, EOM, News, Retail, Warehouse

New vehicle prices remain high—an average of $50,636—keeping both prices and inventory on an upward trajectory since October 2022.

Key Points: 
  • New vehicle prices remain high—an average of $50,636—keeping both prices and inventory on an upward trajectory since October 2022.
  • Used car inventory has increased 17% since the February 1 low of 1.5 million, with inventory expected to reach 1.7 million by month's end.
  • Inventory is increasing overall in both the new and used car markets as new car prices reach new highs, but this slight increase in used car prices this month may suggest that the used car market may not be on a long-term price decline.
  • Here are your key takeaways:
    New car inventory is still on an upward trajectory, despite the slight dip predicted this month.

Richard McDonough, MD Honored for Patient Advocacy Efforts, Receives Dorothy Green Phillips Legacy Award at FLASCO Annual Gala

Retrieved on: 
Thursday, April 20, 2023
Neck, BCPS, Doctor of Pharmacy, Award, Cancer, EOM, Quality, Organization, Phillips, QUEST Honors Fellows Program, Patient, Physician, Gynecologic oncology, Health, FCS, Nursing, MD

FORT MYERS, Fla., April 20, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Richard McDonough, MD, is the recipient of the Florida Society of Clinical Oncology (FLASCO) 2023 Dorothy Green Phillips Legacy Award. The recognition was announced at FLASCO's Annual Gala held on April 14 in Orlando.

Key Points: 
  • FORT MYERS, Fla., April 20, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Richard McDonough, MD , is the recipient of the Florida Society of Clinical Oncology (FLASCO) 2023 Dorothy Green Phillips Legacy Award.
  • The recognition was announced at FLASCO's Annual Gala held on April 14 in Orlando.
  • The Award, named in honor of Dorothy Green Phillips, who retired in 2019 after serving as FLASCO Executive Director, is presented annually to a FLASCO member whose contributions leave a lasting legacy.
  • Phillips, known nationally as a trailblazer of innovative collaboration and a passionate advocate for cancer patients and providers, personally selected Dr. McDonough as this year's honoree.

Florida Cancer Specialists & Research Institute a Top Performer in the Center for Medicare & Medicaid Innovation's Oncology Care Model

Retrieved on: 
Thursday, March 2, 2023
Cropping system, EOM, Cancer, CMS, CMMI, Patient, Navigation, Center for Medicare and Medicaid Innovation, OCM, Medicine, Medicare, Oncology Care Model, ED, FCS, Medical imaging, Hospital, Nursing, Health insurance, MD

FORT MYERS, Fla., March 2, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS), a consistent top performer among the 126 U.S.-based oncology practices that participated in the Center for Medicare & Medicaid Innovation (CMMI) Oncology Care Model (OCM), shares its results in the payment and delivery model's final wave which ended in June 2022 in a newly released case study.

Key Points: 
  • Florida Cancer Specialists & Research Institute, a top performer in OCM, releases a case study on final wave performance
    The intent of the OCM was to improve the quality and cost of care for oncology patients.
  • The model tracked financial and performance measures for episodes of care around the administration of chemotherapy to cancer patients.
  • In the final payment period (PP10) of OCM, FCS reported a net $24.3 million in cost savings to Medicare beneficiaries.
  • FCS Medicare expenditures were 3.6% lower when compared to other OCM participating practices and 5.6% lower than all practices providing cancer care.

EOM PHARMACEUTICAL HOLDINGS, INC. ANNOUNCES NAME CHANGE FROM IMMUNOCELLULAR THERAPEUTICS, LTD.

Retrieved on: 
Thursday, November 10, 2022
Quality of life, EOM, Retina, Rheumatoid arthritis, AIDS, Forward-looking statement, Common stock, Cachexia, M.D, Board, Securities Act of 1933, Degenerative disease, Medicine, Infection, Securities Exchange Act of 1934, Cancer, Patient, Drug Quality and Security Act, Ownership, Industry, OTC Markets Group, Pharmaceutical industry, COVID-19

MONTVALE, N.J., Nov. 10, 2022 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. ("EOM"), a clinical-stage pharmaceutical company, today announced its name change from ImmunoCellular Therapeutics Ltd., to EOM Pharmaceutical Holdings, Inc. EOM's Common Stock will continue to be quoted on the OTC Markets under the ticker symbol "IMUC" while the company completes the process of changing the principal listing of its common stock to a national exchange. No action is required to be taken by company stockholders with respect to the name change.

Key Points: 
  • No action is required to be taken by company stockholders with respect to the name change.
  • The company name change follows the merger of EOM Pharmaceuticals, Inc. and ImmunoCellular Therapeutics Ltd. on December 1, 2021, in which the shareholders of EOM Pharmaceuticals became the majority shareholders of the combined company.
  • For more information about EOM Pharmaceutical Holdings, Inc., please visit www.eompharma.com .
  • EOM assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.